Last reviewed · How we verify
NCT07161635
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
NA trial testing Clareon PanOptix Pro/Pro Toric Trifocal IOL in Aphakia in 110 participants. Participants enrolled and being followed up; not accepting new ones.
1 October 2026
Quick facts
| Lead sponsor | Alcon Research |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 110 |
| Start date | 14 October 2025 |
| Primary completion | 1 October 2026 |
| Estimated completion | 1 October 2026 |
| Sites | 5 locations across United States |
Drugs / interventions tested
- Clareon PanOptix Pro/Pro Toric Trifocal IOL
- Phacoemulsification
Conditions studied
- Aphakia — all drugs for Aphakia →
- Presbyopia — all drugs for Presbyopia →
Sponsor
Alcon Research — full company profile →
Who can join
22 and older, any sex, with Aphakia or Presbyopia. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Mean Binocular Photopic Best Corrected Distance Visual Acuity (BCDVA)
Time frame: Month 1 and Month 6 postoperative
Visual Acuity (VA) will be assessed for both eyes together (binocular) using Early Treatment Diabetic Retinopathy Study (ETDRS) reading charts at a distance of 4 meters from the subject under photopic (well-lit) conditions with correction in place. BCDVA will be measured in logarithm Minimum Angle of Resolution (logMAR). LogMAR values typically range from -0.3 (20/10 vision on the Snellen chart) t
Sponsor's own description
The purpose of this study is to collect safety and performance data on two approved intraocular lenses (IOLs). This study will be conducted in participants who require cataract surgery in both eyes. The IOLs are designed to provide vision at far, arm's length, and near.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07161635
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aphakia
Currently open trials in the same condition.
- NCT06258707 — Bicentric Clinical Investigation to Assess Safety and Performance of LuxBoost IOL · NA · recruiting
Other Alcon Research trials
Trials by the same sponsor.
- NCT06884202 — Evaluation of Delefilcon A Contact Lenses · NA · completed
- NCT06784063 — Visual Performance With Clareon® Vivity® Intraocular Lenses (IOLs) · NA · completed
- NCT06571656 — Evaluation of the Safety and Tolerability of Ocular Lubricants · NA · terminated
- NCT06660290 — A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes · Phase 3 · completed
- NCT06483113 — DAILIES TOTAL1® Soft Contact Lenses - Post-Market Clinical Follow-up Study · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07161635 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alcon Research
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07161635.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing